Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune disease characterized by medium and small vessels inflammation. Cardiac vasculitic involvement is one of the most severe manifestations with a significant impact on patients' long-term prognosis: anyway, a specific therapeutic approach for heart involvement in EGPA has not been explored yet. Current regimen consists of a long-term therapy with high dose of glucocorticoids, causing the well-known related-adverse events; immunosuppressive drugs are used in patients with severe manifestations, with some limitations. New therapeutic approaches are needed for patients with refractory disease or contraindications to conventional therapies. The quest for the ideal therapy is going toward a more and more personalized approach: on the one hand, efforts are made to use already existing therapies in the most appropriate way; on the other hand, new insights into EGPA pathogenesis allow the discovery of new targets, as demonstrated by mepolizumab and rituximab, targeting eosinophils, and B-cell compartments. This review summarizes the emerging therapies used in EGPA, focusing on the most recent studies on biologics and analyzing their efficacy and safety.

Uzzo, M., Regola, F., Trezzi, B., Toniati, P., Franceschini, F., Sinico, R. (2021). Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis. FRONTIERS IN MEDICINE, 8(2 November 2021) [10.3389/fmed.2021.754434].

Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis

Trezzi, Barbara;Sinico, Renato Alberto
Ultimo
2021

Abstract

Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune disease characterized by medium and small vessels inflammation. Cardiac vasculitic involvement is one of the most severe manifestations with a significant impact on patients' long-term prognosis: anyway, a specific therapeutic approach for heart involvement in EGPA has not been explored yet. Current regimen consists of a long-term therapy with high dose of glucocorticoids, causing the well-known related-adverse events; immunosuppressive drugs are used in patients with severe manifestations, with some limitations. New therapeutic approaches are needed for patients with refractory disease or contraindications to conventional therapies. The quest for the ideal therapy is going toward a more and more personalized approach: on the one hand, efforts are made to use already existing therapies in the most appropriate way; on the other hand, new insights into EGPA pathogenesis allow the discovery of new targets, as demonstrated by mepolizumab and rituximab, targeting eosinophils, and B-cell compartments. This review summarizes the emerging therapies used in EGPA, focusing on the most recent studies on biologics and analyzing their efficacy and safety.
Articolo in rivista - Review Essay
biologics; Eosinophilic Granulomatosis with Polyangiitis; heart involvement; mepolizumab; novel therapies; omalizumab; rituximab;
English
2-nov-2021
2021
8
2 November 2021
754434
none
Uzzo, M., Regola, F., Trezzi, B., Toniati, P., Franceschini, F., Sinico, R. (2021). Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis. FRONTIERS IN MEDICINE, 8(2 November 2021) [10.3389/fmed.2021.754434].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/334084
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
Social impact